6/29/23, 1:44 AM PlasmAr Pathway Feedback Search Clinical Topics Home Studies PlasmAr PlasmAr Disease COVID 19 infection Trial question What is the role of convalescent plasma in severe coronavirus 2019 pneumonia? Study design Multi-center Double blinded RCT Population Characteristics of study participants 32.3% female N = 334 67.7% male 334 patients (108 female, 225 male) Inclusion criteria: hospitalized adult patients with SARS-CoV-2 pneumonia Key exclusion criteria: pregnancy or lactation, a history of blood component allergies, an infectious cause of pneumonia other than SARS-CoV-2, requirement for mechanical ventilation, multiorgan failure Interventions N=228 convalescent plasma (a single administration of COVID-19 convalescent plasma in addition to standard treatment) N=105 placebo (normal saline solution plus standard treatment) Primary outcome https://web.pathway.md/studies/recnWm7mteXf0uurD 1/2 6/29/23, 1:44 AM PlasmAr Pathway Death at 30 days 11.4 % 11.43 10.96 8.6 % 5.7 % 2.9 % No significant difference 0.0 % Convalescent plasma Placebo No significant difference in death at 30 days (10.96% vs. 11.43%; ARD -0.46, 95% CI -7.8 to 6.8) Secondary outcomes No significant difference in median time from intervention to hospital discharge (13 days vs. 12 days; subHR 0.99, 99% CI 0.75 to 1.32) No significant difference in median time from intervention to complete restoration of physical functions (15 days vs. 15 days; subHR 0.89, 95% CI 0.66 to 1.18) Safety outcomes No significant difference in adverse and serious adverse events. Significant difference in infusion-related adverse events (4.8% vs. 1.9%). Conclusion In hospitalized adult patients with SARS-CoV-2 pneumonia, convalescent plasma was not superior to placebo with respect to death at 30 days. Reference Ventura A Simonovich, Leandro D Burgos Pratx, Paula Scibona et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619-629. Open reference URL https://web.pathway.md/studies/recnWm7mteXf0uurD 2/2